Evidence map›Paper›PMID 41012516›Full record

ReviewPharmaceutics2025

Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.

Pedro Brivaldo Viana da Silva, Thiécla Katiane Osvaldt Rosales, João Paulo Fabi

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pedro Brivaldo Viana da SilvaDepartment of Food Science and Experimental Nutrition, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-220, SP, Brazil.
Thiécla Katiane Osvaldt RosalesDepartment of Food Science and Experimental Nutrition, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-220, SP, Brazil.ORCID 0000-0001-9653-7117
João Paulo FabiDepartment of Food Science and Experimental Nutrition, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-220, SP, Brazil.ORCID 0000-0002-7430-7756

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2022/12270-1; 2024/22823-3; 2023/09620-3; 2013/07914-8; 2022/12834-2; 2023/01396-7National Council for Scientific and Technological Development 307842/2022-3; 151150/2023-0
6 · The paper itself

Abstract

The human gastrointestinal tract contains a complex and diverse community of microorganisms, referred to as the gut microbiota. Due to their close proximity to human cells, these microorganisms play a crucial role in maintaining the host's health, influencing various metabolic processes, and providing protection against potentially harmful agents and pathogens. The disruption in this microbial ecosystem, known as dysbiosis, is associated with inflammatory and metabolic diseases, as well as certain types of cancer. Strategies to modulate the microbiota toward a state of homeostasis through the use of "biotics" (probiotics, prebiotics, synbiotics, and postbiotics) have increased. However, challenges such as low stability, loss of microbial viability, and difficulties in delivery to the intestine significantly decrease the progress of their clinical and nutritional applications. Microencapsulation and nanoencapsulation technologies offer potential solutions to enhance the stability, bioavailability, and controlled release of microorganisms and/or bioactive compounds within the gastrointestinal tract. Considering these aspects, this review provides a comprehensive overview of recent advances in nanoencapsulation techniques for biotics, highlighting their mechanisms of action, potential health benefits, and applications in functional foods and targeted therapies. Furthermore, it addresses existing limitations, evaluates feasibility, and discusses the future potential of these technologies in promoting gut health and disease prevention. Further research, especially through clinical studies, is mandatory to verify the safety and effectiveness of nanoencapsulated biotics and to obtain regulatory approval.

Indexed as

gut microbiotananoencapsulationpostbioticsprebioticsprobioticssynbiotics

Identifiers

PMID41012516
PMCPMC12473147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.